Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01222715
First received: October 15, 2010
Last updated: June 8, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)